|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,090.80 INR | +1.79% |
|
+3.23% | +6.48% |
| Capitalization | 1,38500Cr 1.52TCr 1.31TCr 1.21TCr 1.13TCr 2.11TCr 2.27TCr 14TCr 5.53TCr 66TCr 5.71TCr 5.6TCr 2,40900Cr | P/E ratio 2026 * |
56.2x | P/E ratio 2027 * | 46.2x |
|---|---|---|---|---|---|
| Enterprise value | 1,40100Cr 1.54TCr 1.32TCr 1.23TCr 1.15TCr 2.14TCr 2.3TCr 14TCr 5.59TCr 67TCr 5.78TCr 5.66TCr 2,43700Cr | EV / Sales 2026 * |
10.7x | EV / Sales 2027 * | 9.43x |
| Free-Float |
30.26% | Yield 2026 * |
0.72% | Yield 2027 * | 0.83% |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | +1.79% | ||
| 1 week | +3.23% | ||
| Current month | +6.48% | ||
| 1 month | +8.81% | ||
| 3 months | +14.30% | ||
| 6 months | +16.15% | ||
| Current year | +6.48% |
| 1 week | 3,908 |  | 4,107.55 |
| 1 month | 3,748.4 | | 4,107.55 |
| Current year | 3,829.25 | | 4,107.55 |
| 1 year | 2,891.45 | | 4,107.55 |
| 3 years | 1,446.15 | | 4,107.55 |
| 5 years | 1,155.65 | | 4,107.55 |
| 10 years | 571.75 | | 4,107.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 01/08/2025 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 01/09/2018 |
| Compliance Officer | - | 01/08/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 30/07/2014 | |
| Director/Board Member | 46 | 08/02/2018 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 07/03/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | +3.23% | +28.72% | +152.94% | 1.5TCr | |
| +0.53% | -2.37% | +43.09% | +194.99% | 93TCr | |
| -0.41% | +6.98% | +48.72% | +28.81% | 53TCr | |
| -1.11% | -2.60% | +24.94% | +43.67% | 38TCr | |
| -0.60% | +1.26% | +29.94% | +17.78% | 37TCr | |
| -1.15% | -1.63% | +28.68% | +21.63% | 29TCr | |
| -0.03% | +1.51% | +29.51% | +36.74% | 28TCr | |
| -1.93% | -1.54% | +11.14% | +0.04% | 27TCr | |
| -2.92% | -0.41% | -31.52% | -21.19% | 27TCr | |
| +0.12% | +1.32% | +21.43% | +24.97% | 18TCr | |
| Average | -0.61% | +0.78% | +23.46% | +50.04% | 35.06TCr | |
| Weighted average by Cap. | -0.60% | +0.51% | +28.98% | +67.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13TCr 143.57Cr 123.31Cr 114.41Cr 106.9Cr 199.01Cr 213.86Cr 1.32TCr 520.65Cr 6.21TCr 538.41Cr 527.35Cr 23TCr | 15TCr 161.94Cr 139.09Cr 129.05Cr 120.58Cr 224.48Cr 241.22Cr 1.49TCr 587.27Cr 7.01TCr 607.3Cr 594.83Cr 26TCr |
| Net income | 2.44TCr 27Cr 23Cr 21Cr 20Cr 37Cr 40Cr 246.77Cr 97Cr 1.16TCr 100.51Cr 98Cr 4.24TCr | 3.02TCr 33Cr 29Cr 26Cr 25Cr 46Cr 50Cr 305.98Cr 120.51Cr 1.44TCr 124.62Cr 122.06Cr 5.25TCr |
| Net Debt | 1.62TCr 18Cr 15Cr 14Cr 13Cr 25Cr 27Cr 164.61Cr 65Cr 773.44Cr 67Cr 66Cr 2.83TCr | 296.05Cr 3.26Cr 2.8Cr 2.6Cr 2.43Cr 4.52Cr 4.85Cr 30Cr 12Cr 140.95Cr 12Cr 12Cr 515.1Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | 4,090.80 ₹ | +1.79% | 6,970 |
| 16/26/16 | 4,018.75 ₹ | +0.35% | 2,748 |
| 14/26/14 | 4,004.85 ₹ | +1.66% | 2,225 |
| 13/26/13 | 3,939.55 ₹ | -0.22% | 2,821 |
| 12/26/12 | 3,948.25 ₹ | -0.37% | 1,637 |
Delayed Quote Bombay S.E., January 19, 2026 at 03:50 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition